|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 2 | Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European association for percutaneous cardiovascular in- terventions(EAPCl)/stent for Iife(SFL) groups显示文摘 | Noc M Fajadet J Lassen J F | 2014 | Euro Inter- vention2014，10，1： | 1 |
| 3 | Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas显示文摘 | Lassen D Jensen L H Soremen M A | 2011 | Acta Oncol2011，50，3： | 1 |
| 4 | The consensus concept for thermostability engineering of proteins 显示文摘 | Lehmann M Pasamontes L Lassen SF Wyss M | 2000 | Biochimica et Biophysica Acta (BBA) -Protein Structure and Molecular Enzy- mology2000，1543，2： | 1 |
| 5 | Nitric-oxide synthase inhibition in migraine 显示文摘 | Lassen L H Ashina M Christiansen I | 1997 | Lancet1997，349，9049： | 1 |
| 6 | Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer - a Danish Oncological Lung Cancer Group (DOLG) phase Ⅱ trial显示文摘 | Sorensen M Lassen U Palshof T | 2008 | Lung Cancer2008，60，2： | 1 |
| 7 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial显示文摘 | Turpie A G Lassen M R Davidson B L | 2009 | Lancet2009，373，9676： | 1 |
| 8 | Consensus review of optimal perioperative care in colorectal surgery:Enhanced Recovery After Surgery (ERAS) Group recommendations 显示文摘 | Lassen K Soop M Nygren J | 2009 | Arch Surg2009，144，10： | 1 |
| 9 | Genetic relationship between body condition score, dairy character, mastitis, and diseases other than mastitis in first-parity Danish Holstein cows显示文摘 | Lassen J Hansen M Sorensen M K | 2003 | Journal of dairy science2003，86，： | 1 |
| 10 | Consensus review of optimal perioperative care in eoloreetal surgery: En-hanced Recovery After Surgery (ERAS) Group recom- mendations显示文摘 | Lassen K Soop M Nygren J | 2009 | Arch Surg2009，144，10： | 1 |
| 11 | Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients显示文摘 | Osterlind K Hansen M | 1995 | Clin Oncol1995，13，5： | 1 |
| 12 | Consensus review of optimal peri -operative care in colorectal surgery :Enhanced Recovery AfterSurgery (ERAS) Group recommendations显示文摘 | Lassen K Soop M Nygren J | 2009 | Arch Surg2009，144，10： | 1 |
| 13 | A phase I, dose-esca-lation study of TB-403 , a monoclonal antibody directed againstPIGF,in patients with advanced solid tumors 显示文摘 | Lassen U Nielsen DL S0rensen M | 2012 | Br J Cancer2012，106，4： | 1 |
| 14 | A phaseⅠstudy of the safety and pharmacokinetics of the histonedeacetylase inhibitor belinostat administered in combina-tion with carboplatin and/or paclitaxel in patients with sol-id tumours显示文摘 | Lassen U Molife LR Sorensen M | 2010 | Br J Cancer2010，103，1： | 1 |
| 15 | Quantum optical coherence can survive photon losses using a continuous-variable quantum erasure-correcting code显示文摘 | Lassen M Sabuncu M Huck A | | 0，，10： | 1 |
| 16 | Rivarox- aban versus enoxaparin for thromboprophylaxis after total knee arthroplasty(RECORD4) : a randomised tri- al显示文摘 | Turpie A G Lassen M R Davidson B L | 2009 | Lancet2009，373，9676： | 1 |
| 17 | Phase II study of bevaci- zumab and temsirolimus combination therapy for recurrent glioblas- toma multiforme 显示文摘 | Lassen U Sorensen M Gaziel TB | 2013 | Anticaneer Research2013，33，4： | 1 |
| 18 | Determination of pcdds, pcdfs, pcbs and hcb emissions from the metallurgical sector in poland显示文摘 | Grochowalski A Lassen C Holtzer M | 2007 | Environmental Science and Pollution Research International2007，14，5： | 1 |
| 19 | A phase I- 1I dose escalation study of fixed- dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas 显示文摘 | Lassen U Jensen LH Sorensen M | 2011 | Acta Oncol2011，50，： | 1 |
| 20 | RE- CORD 3 investigatiors, rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty显示文摘 | MICHAEL R LASSEN M D WALTER A M D | 2008 | N Engl J Med2008，358，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员